Scarica l'app Stockscreener
11.70
0.17%
0.02
Dopo l'orario di chiusura:
11.70
Precedente Chiudi:
$11.68
Aprire:
$11.68
Volume 24 ore:
77,693
Relative Volume:
0.65
Capitalizzazione di mercato:
$144.19M
Reddito:
$3.25M
Utile/perdita netta:
$-116.80M
Rapporto P/E:
-3.8361
EPS:
-3.05
Flusso di cassa netto:
$-98.17M
1 W Prestazione:
+34.17%
1M Prestazione:
+57.47%
6M Prestazione:
+21.87%
1 anno Prestazione:
-55.55%
Intervallo 1D:
$11.36
$12.40
Intervallo di 1 settimana:
$9.04
$12.40
Portata 52W:
$5.6652
$27.84
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Nome
Rapt Therapeutics Inc
Settore
Industria
Telefono
(650) 489-9000
Indirizzo
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Confronta RAPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
11.70 | 144.19M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-22 | Ripresa | H.C. Wainwright | Buy |
| 2024-12-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | Downgrade | Stifel | Buy → Hold |
| 2024-11-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-11-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-05-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-02-22 | Downgrade | UBS | Buy → Neutral |
| 2024-02-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-21 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | Iniziato | Evercore ISI | Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-09-14 | Iniziato | Berenberg | Buy |
| 2023-08-09 | Iniziato | Stifel | Buy |
| 2023-06-15 | Iniziato | Barclays | Overweight |
| 2023-01-04 | Iniziato | Guggenheim | Buy |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2022-09-21 | Iniziato | CapitalOne | Overweight |
| 2022-05-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-12-09 | Iniziato | JP Morgan | Overweight |
| 2021-08-12 | Iniziato | SVB Leerink | Outperform |
| 2021-06-21 | Iniziato | Piper Sandler | Overweight |
| 2020-06-01 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-13 | Iniziato | ROTH Capital | Buy |
| 2019-11-25 | Iniziato | BMO Capital Markets | Outperform |
| 2019-11-25 | Iniziato | UBS | Buy |
| 2019-11-25 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Rapt Therapeutics Inc Borsa (RAPT) Ultime notizie
RAPT Therapeutics Inc. Stock Analysis and ForecastFree Stock Selection - PrintWeekIndia
What analysts say about RAPT Therapeutics Inc. stockRapid growth trajectories - Autocar Professional
Is RAPT Therapeutics Inc. a good long term investmentHigh-performance investment picks - jammulinksnews.com
What drives RAPT Therapeutics Inc. stock priceUnstoppable profit momentum - jammulinksnews.com
What makes RAPT Therapeutics Inc. stock price move sharplyHigh Win Rate Stock Ideas - Newser
How RAPT Therapeutics Inc. stock performs during market volatilityTop Performer Shortlist - Newser
Why RAPT Therapeutics Inc. stock attracts strong analyst attentionSafe Entry High Exit Alerts - Newser
Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why - Yahoo Finance
RAPT Therapeutics Explodes 20%—What's Fueling the Surge? - AInvest
RAPT Therapeutics Soars 24%—What’s Fueling the Breakout? - AInvest
Best Momentum Stocks to Buy for July 15th - TradingView
Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect? - Yahoo Finance
HC Wainwright Analysts Decrease Earnings Estimates for RAPT - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Rapt Therapeutics (NASDAQ:RAPT) Stock - Defense World
Rapt Therapeutics (NASDAQ:RAPT) Price Target Raised to $27.00 - Defense World
RAPT Therapeutics Unveils Plans for RPT904 Development - TipRanks
Rapt Therapeutics (NASDAQ:RAPT) Given Average Rating of “Hold” by Analysts - Defense World
RAPT Therapeutics Expands Board with New Appointments - TipRanks
Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know - Yahoo Finance
RAPT Therapeutics Executes 1-for-8 Reverse Stock Split - TipRanks
RAPT Therapeutics (RAPT) Trading Halted as News Awaits Release | RAPT Stock News - GuruFocus
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Rapt Therapeutics announces effective date for 1-for-8 reverse stock split - Yahoo Finance
# RAPT Therapeutics to implement 1-for-8 reverse stock split By Investing.com - Investing.com South Africa
RAPT Finalizes Reverse Split Plan; 1-for-8 Ratio Effective June 16, 2025 - Nasdaq
RAPT Therapeutics Shares to Start Trading on a Split-Adjusted Basis Tuesday - marketscreener.com
RAPT Therapeutics Announces Effective Date For 1-For-8 Reverse Stock Split - MarketScreener
RAPT Therapeutics Announces Reverse Stock Split Effective June 2025 | RAPT Stock News - GuruFocus
# RAPT Therapeutics to implement 1-for-8 reverse stock split - Investing.com
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split - GlobeNewswire
RAPT Therapeutics Announces Major Share Consolidation: 132M Shares Shrinking to 16.5M in Reverse Split - Stock Titan
Two Sigma Investments LP Sells 339,957 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Transcript : RAPT Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 09 - MarketScreener
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position - MSN
RAPT Therapeutics Announces Development Plans for RPT904 - TipRanks
Rapt Therapeutics Inc Azioni (RAPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):